MiRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjogren's syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis.

ABSTRACT: Sjögren's syndrome (SS) is an autoimmune disease primarily affecting salivary glands, with xerostomia as a distinct clinical manifestation. This disease also poses a significantly increased risk of lymphoma, severely impacting patients' quality of life. The imbalance between Th17 and Treg cells plays a critical role in SS progression, driving severe immune dysregulation, chronic inflammation, and escalating tissue dysfunction. However, current clinical treatments for SS still remain limited, and it continues to be recognized as a refractory disease. Therefore, the development of novel and effective therapeutic strategies is a pressing demand in clinical research. In recent years, extracellular vesicle (EV) therapy has emerged as a promising approach for autoimmune disease treatment, showin

SUBMITTER: Xie Y 

PROVIDER: S-EPMC11927278 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature